Saltar al contenido
Merck

Myeloid Tribbles 1 induces early atherosclerosis via enhanced foam cell expansion.

Science advances (2019-11-07)
Jessica M Johnston, Adrienn Angyal, Robert C Bauer, Stephen Hamby, S Kim Suvarna, Kajus Baidžajevas, Zoltan Hegedus, T Neil Dear, Martin Turner, Heather L Wilson, Alison H Goodall, Daniel J Rader, Carol C Shoulders, Sheila E Francis, Endre Kiss-Toth
RESUMEN

Macrophages drive atherosclerotic plaque progression and rupture; hence, attenuating their atherosclerosis-inducing properties holds promise for reducing coronary heart disease (CHD). Recent studies in mouse models have demonstrated that Tribbles 1 (Trib1) regulates macrophage phenotype and shows that Trib1 deficiency increases plasma cholesterol and triglyceride levels, suggesting that reduced TRIB1 expression mediates the strong genetic association between the TRIB1 locus and increased CHD risk in man. However, we report here that myeloid-specific Trib1 (mTrib1) deficiency reduces early atheroma formation and that mTrib1 transgene expression increases atherogenesis. Mechanistically, mTrib1 increased macrophage lipid accumulation and the expression of a critical receptor (OLR1), promoting oxidized low-density lipoprotein uptake and the formation of lipid-laden foam cells. As TRIB1 and OLR1 RNA levels were also strongly correlated in human macrophages, we suggest that a conserved, TRIB1-mediated mechanism drives foam cell formation in atherosclerotic plaque and that inhibiting mTRIB1 could be used therapeutically to reduce CHD.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Suero de cabra
Sigma-Aldrich
IGEPAL® CA-630, for molecular biology
Sigma-Aldrich
Anti-Tribbles-1 Antibody, Upstate®, from rabbit